NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
1.810
+0.060 (3.43%)
At close: Jun 23, 2026, 4:00 PM EDT
1.840
+0.030 (1.66%)
After-hours: Jun 23, 2026, 6:55 PM EDT
NextCure Employees
NextCure had 40 employees as of December 31, 2025. The number of employees decreased by 3 or -6.98% compared to the previous year.
Employees
40
Change (1Y)
-3
Growth (1Y)
-6.98%
Revenue / Employee
n/a
Profits / Employee
-$1,366,600
Market Cap
6.54M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 40 | -3 | -6.98% |
| Dec 31, 2024 | 43 | -39 | -47.56% |
| Dec 31, 2023 | 82 | -17 | -17.17% |
| Dec 31, 2022 | 99 | 12 | 13.79% |
| Dec 31, 2021 | 87 | -3 | -3.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Bolt Biotherapeutics | 23 |
| Imunon | 20 |
| NuCana | 12 |
| CNS Pharmaceuticals | 8 |
| Ernexa Therapeutics | 7 |
| Immuron | 7 |
| PharmaCyte Biotech | 2 |
NXTC News
- 5 days ago - NextCure Transcript: AGM 2026 - Transcripts
- 19 days ago - NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - GlobeNewsWire
- 21 days ago - NextCure Transcript: KOL event - Transcripts
- 21 days ago - NextCure Press release: KOL event - Filings
- 21 days ago - NextCure Slides: KOL event - Filings
- 21 days ago - NextCure share weakness overdone, says Lucid Capital - TheFly
- 22 days ago - NextCure presents Phase 1 data for SIM0505 in gynecologic cancers - TheFly
- 22 days ago - NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - GlobeNewsWire